Vaccine Co-Administration and Interchangeability

Principles Of Vaccine Co-Administration

Co-administration refers to administering two or more vaccines at different injection sites during the same clinical visit.
Strategy serves as a resource-saving means to obtain maximum health benefit.
Allows efficient adoption and implementation of new vaccines.
Reduces missed vaccination opportunities.
Increases convenience for vaccines and healthcare providers.
Reduces total number of vaccination consultations and associated costs.
Facilitates timely administration of vaccines and raises compliance with recommendations.
Yields immune responses and adverse reaction rates similar to separate administration of the same vaccines.

Administer different inactivated or subunit vaccines simultaneously or at any interval between doses.
Administer multiple live parenteral or intranasal vaccines simultaneously.
Separate live vaccines by a minimum of four weeks if not administered simultaneously.
Administer live and inactivated vaccines simultaneously or at any time interval between doses.
Maintain a minimum interval of four weeks between two doses of the identical vaccine to ensure adequate immune response, with rabies vaccine serving as the only exception.
Count vaccine doses administered up to four days before the minimum interval or age as valid.
Repeat live vaccines administered less than four weeks apart, ensuring a four-week gap from the first dose.

Vaccine Combination	Specific Administration Rule
Pneumococcal conjugate and pneumococcal polysaccharide	Conjugate vaccine must precede polysaccharide vaccine by a minimum of eight weeks to improve immunogenicity.
Pneumococcal conjugate and meningococcal conjugate (Menactra)	Pneumococcal Conjugate vaccine must precede meningococcal vaccine by a minimum of four weeks in patients with functional or anatomic asplenia, or human immunodeficiency virus.
Varicella and smallpox	Separate administration strictly required.

Utilize separate needles and syringes for each injected vaccine.
Avoid mixing different vaccines in a single syringe unless explicitly approved and licensed by the manufacturer.
Inject simultaneous vaccines at different anatomic sites whenever possible.
Separate simultaneous intramuscular injections in the same limb by a minimum of one inch or three centimeters.
Prioritize anterolateral thigh for simultaneous intramuscular injections in infants and younger children due to greater muscle mass.
Prioritize deltoid muscle for older children and adults receiving multiple intramuscular injections.
Administer highly reactogenic vaccines, including diphtheria, tetanus, acellular pertussis, meningococcal B, and pneumococcal vaccines, in different limbs.
Administer most painful vaccines last during the clinical visit.
Separate injection sites completely when administering a specific vaccine alongside its corresponding immune globulin.
Observe patients for allergic reactions or anaphylaxis for fifteen to twenty minutes following immunization.

Vaccine interchangeability is defined as administering similar vaccines from different manufacturers to the same individual over time.
Necessitated by vaccine shortages, contraindications to specific products, changes in product availability, or migration across different jurisdictions.
Maintain the identical manufacturer’s product for all doses within a primary vaccine series whenever feasible.
Substitute with a different brand rather than deferring routine immunization if the original product remains unknown or unavailable.
Expect comparable safety, reactogenicity, immunogenicity, and efficacy when interchanging standard vaccine components.

Vaccines require authorization for identical indications and equally acceptable schedules.
Vaccines require authorization for the identical target population.
Vaccines must contain comparable type and quantity of antigen.
Variations in production methods, antigen concentrations, adjuvants, conjugating proteins, stabilizers, and preservatives can influence interchangeability potential.
Vaccine diluents remain strictly product-specific and are never interchangeable.
Reconstitute lyophilized vaccines utilizing only the specific diluent provided by the respective manufacturer.

Coronavirus disease: Any available authorized vaccine completes a primary series initiated with another product.
Hepatitis A: Monovalent vaccines remain fully interchangeable. Any age-appropriate vaccine provides an effective booster dose.
Hepatitis B: Monovalent vaccines remain fully interchangeable using manufacturer-recommended schedules. Hepatitis A and B combination vaccine completes the hepatitis B primary series.
Influenza: Prefer identical vaccine type for both doses in children requiring two doses during the same season. Utilize any age-appropriate alternative if the initial type remains unavailable.
Measles, mumps, and rubella: Authorized vaccines remain fully interchangeable based on expert consensus.
Rotavirus: Avoid interchanging monovalent and pentavalent rotavirus vaccines due to distinct compositions and schedules. Complete series with available product if previous product remains unknown. Administer a total of three doses if any previous dose involved the pentavalent vaccine.
Varicella: Complete the two-dose schedule with identical univalent varicella or combination measles, mumps, rubella, and varicella vaccine unless unavoidable barriers exist.
Rabies: Complete series with identical product whenever possible. Vaccines remain fully interchangeable if identical product proves unfeasible. Pre-exposure prophylaxis boosters accept either formulation.

Diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b: Complete routine primary series with appropriate combination vaccine from identical manufacturer whenever possible. Utilize alternative combination vaccine from different manufacturer if original remains unknown or unavailable. Administer booster doses using appropriate product from any manufacturer.
Meningococcal conjugate: Complete infant primary series with identical vaccine when possible. Utilize any quadrivalent conjugate vaccine for revaccination regardless of initial vaccine brand.
Typhoid: Presume full interchangeability for booster doses regardless of initial formulation administered.